Literature DB >> 30515448

Comment on "Is it Useful to Classify PSP and CBD as Different Disorders?"

Anthony E Lang1.   

Abstract

Entities:  

Year:  2018        PMID： 30515448      PMCID： PMC6207123          DOI： 10.1002/mdc3.12676

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN： 2330-1619


× No keyword cloud information.
  5 in total

Review 1.  Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.

Authors:  Adam L Boxer; Jin-Tai Yu; Lawrence I Golbe; Irene Litvan; Anthony E Lang; Günter U Höglinger
Journal:  Lancet Neurol       Date:  2017-06-13       Impact factor: 44.182

2.  Is it Useful to Classify PSP and CBD as Different Disorders? Yes.

Authors:  Helen Ling; Antonella Macerollo
Journal:  Mov Disord Clin Pract       Date:  2018-03-06

3.  Is it Useful to Classify Progressive Supranuclear Palsy and Corticobasal Degeneration as Different Disorders? No.

Authors:  Günter U Höglinger
Journal:  Mov Disord Clin Pract       Date:  2018-03-06

4.  Tau prions from Alzheimer's disease and chronic traumatic encephalopathy patients propagate in cultured cells.

Authors:  Amanda L Woerman; Atsushi Aoyagi; Smita Patel; Sabeen A Kazmi; Iryna Lobach; Lea T Grinberg; Ann C McKee; William W Seeley; Steven H Olson; Stanley B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  2016-11-28       Impact factor: 11.205

5.  Pathological Tau Strains from Human Brains Recapitulate the Diversity of Tauopathies in Nontransgenic Mouse Brain.

Authors:  Sneha Narasimhan; Jing L Guo; Lakshmi Changolkar; Anna Stieber; Jennifer D McBride; Luisa V Silva; Zhuohao He; Bin Zhang; Ronald J Gathagan; John Q Trojanowski; Virginia M Y Lee
Journal:  J Neurosci       Date:  2017-10-20       Impact factor: 6.167
  5 in total
  1 in total

1.  Presynaptic Striatal Dopaminergic Function in Atypical Parkinsonism: A Metaanalysis of Imaging Studies.

Authors:  Valtteri Kaasinen; Tuomas Kankare; Juho Joutsa; Tero Vahlberg
Journal:  J Nucl Med       Date:  2019-04-12       Impact factor: 10.057
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.